An interventional study of Hybrid Endurance Strength Training and Usual Care in Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), sponsored by University of Malaya. Not yet recruiting at 1 site in Malaysia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by University of Malaya · Not applicable, Interventional, and Treatment
Cardiac rehabilitation (CR) participation remains suboptimal, partly due to logistical challenges and limited access to center-based programs. Hybrid Endurance-Strength Training (HybEST) offers an alternative model by combining supervised endurance and strength exercises with home-based components. The main questions it aims to answer are:
This single-center, two-arm parallel randomized clinical trial aims to evaluate the effects of HybEST on health-related outcomes and quality of life among patients with coronary artery disease in Phase II CR. Eligible participants will be randomly assigned in a 1:1 ratio to either the HybEST intervention group or the standard CR control group using a lottery method, specifically the sealed envelope approach. Assessments will be conducted at baseline (T0), Week 5 (T2), and Week 9 (T3) to measure changes in health-related outcomes and quality of life.
In recent years, models for delivering cardiac rehabilitation (CR) have advanced by incorporating structured exercise methods and technology into routine practice. Hybrid Endurance-Strength Training (HybEST) combines supervised center-based sessions with home-based elements, supported by digital tools such as remote monitoring and virtual consultations. This hybrid approach may help overcome common barriers to CR participation, including travel distance, scheduling conflicts, and work commitments. This single-centre, two-arm parallel randomized controlled trial aims to evaluate the effects of a hybrid exercise program in patients with coronary heart disease. The objectives are;
A total of 84 eligible participants (42 per group, accounting for 14% attrition) will be randomized into either the intervention or control group. The usual care group will follow a standard exercise program consisting of endurance and strength components. This program includes supervised exercise sessions at the center once a week for eight weeks, along with educational materials on exercising at home. The intervention group will participate in a hybrid training program that combines endurance and strength training over eight weeks. Their program includes two supervised sessions at the center and 22 unsupervised sessions at home. Participants will receive exercise educational videos via WhatsApp (Weeks 1-8) and a fitness tracker to support unsupervised sessions. Weekly virtual follow-ups will be conducted from Week 1 to Week 8. Outcome measures include Exercise Capacity, Body Composition, Muscle Strength, Physical Activity and METs, Barrier Scales, and Health-Related Quality of Life. Data will be analyzed using IBM SPSS version 26.0, with statistical significance set at p \< 0.05.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 84 is below the median of 124 across 3,006 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →University of Malaya is the lead sponsor of 284 studies on the registry; 58 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HybEST will be delivered three times weekly over eight weeks; there will be two supervised sessions at the center and 22 unsupervised sessions at home.
Other: Hybrid Endurance Strength Training
The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
Other: Usual Care
HybEST will be delivered three times weekly over eight weeks, with two supervised sessions at the center and 22 unsupervised sessions at home. The exercise characteristics of supervised HybEST and unsupervised HybEST are described. Monitoring methods for unsupervised HybEST include a wearable tracking device that collects data on patients' health parameters (arterial oxygen saturation (SpO2), heart rate, and blood pressure) and weekly phone calls. The unsupervised sessions will include video material on the home-based exercise program.
Also known as: HyBEST
The UC group participants will participate in combined endurance and strength training similar to the intervention group's weekly center-based session over eight weeks.
Also known as: UC
Treadmill stress test
A treadmill stress test will be used to assess the participant's exercise capacity. This type of stress testing is typically performed with the Bruce protocol on either a treadmill or an ergometer, monitored with electrocardiography (ECG) and blood pressure. The Bruce protocol requires participants to complete successive 3-minute stages, with each stage increasing in walking speed and incline. During the test, data on heart rate (HR), blood pressure (BP), and ECG changes will be recorded at the end of each stage. After testing, a report will be generated outlining (i) ECG interpretation and baseline HR and BP, (ii) exercise-induced changes in ECG, (iii) maximum heart rate and blood pressure during exercise, (iv) estimated exercise capacity in metabolic equivalents (METs), (v) exercise duration and stage completed, and (vi) symptoms experienced during exercise and reasons for test termination.
Time frame: Day 0, Week 9
Body composition
Body composition, including body mass index (BMI), body fat percentage, lean mass percentage, and weight in kilograms, will be measured using the bioimpedance meter (OMRON HBF-500INT). Participants' height (meters) will be recorded with the SECA stadiometer. To determine waist circumference, the midpoint between the front-back hip bone and the bottom rib border will be identified when the subject is upright. The average will be calculated by dividing the sum of the two measurements by two.
Time frame: Day 0, Week 5, Week 9
Muscle strength
The strength of major muscles in the upper and lower limbs will be measured using a handheld dynamometer (HHD). A plinth-mounted seat and armrest are provided for the participant's positioning and restraint during HHD testing.
Time frame: Day 0, Week 5, Week 9
Functional Capacity
The goal of the Six-Minute Walk Test (6MWT) is for participants to walk as far as they can at a comfortable pace. Every minute, patients will receive standardized encouragement such as "You are doing well" or "Keep up the good work," along with a reminder of the remaining time. Qualified personnel will walk behind the patient to supervise the test. During the test, patients are allowed to stop if necessary, but they will be advised to resume walking as soon as possible. Patients may use their walking aids during the test, and 6MWD will be recorded in meters. Heart rate (HR) and oxygen saturation (SpO2) will be measured before, during, and after the 6MWT using pulse oximetry (Model 2500, Nonin Medical, Inc., Minneapolis, MN, USA).
Time frame: Day 0, Week 5, Week 9
Physical Activity
The International Physical Activity Questionnaire (IPAQ) will be used to assess the level of physical activity based on information about the time spent walking, participating in moderate-to-vigorous activities, and avoiding sedentary behavior during the previous seven days. According to participant responses, physical activity is categorized into three levels: moderate (600-3000 MET minutes/week), vigorous (more than 3000 MET minutes/week), and light (less than 600 MET minutes/week).
Time frame: Day 0, Week 5, Week 9
Total Energy Expenditure
METs will be assessed using a treadmill stress test conducted according to standard protocols (e.g., Bruce or Modified Bruce). Participants will exercise until they reach volitional fatigue or achieve predetermined termination criteria based on clinical guidelines. The highest workload achieved, expressed in METs, will be calculated from the treadmill speed and grade at peak exercise.
Time frame: Day 0, Week 5, Week 9
Health-related Quality of Life
The Medical Outcomes Study Short Form Health Survey (SF-36) will be used to evaluate a person's health status. The SF-36 questionnaire is a standardized tool with 36 items that measure eight different subscales, which cover various aspects of physical functioning, role functioning, physiological discomfort, general health, vitality, social functioning, role-emotional, and mental health. Both individual subscale scores and two summary scores, known as the physical component summary score (PCS) and mental component summary score (MCS), can be calculated.
Time frame: Day 0, Week 9
Self-efficacy
The Self-efficacy to Exercise (SEE) questionnaire consists of nine items. The overall score is the sum of all answers to these questions, with total scores ranging from 0 to 90. A higher score indicates greater self-efficacy for exercising.
Time frame: Day 0, Week 9
Barriers to participation
To identify barriers to CR participation, participants will complete a self-administered Cardiac Rehabilitation Barriers Scale (CRBS) questionnaire. It uses a 5-point Likert scale, from 1 (strongly disagree) to 5 (strongly agree), to rate the items. The CRBS includes four subscales: three items about job and time conflicts; five items on logistical issues such as cost, distance, and transportation; nine items concerning perceived needs and healthcare factors; and four related to comorbidities and functional status. Higher ratings indicate more obstacles to enrolling in a CR.
Time frame: Day 0, Week 9
Participation and adherence rate
Participation and adherence rates will be documented through self-reflected forms and diaries. Participation rate is defined as the proportion of patients who accepted to participate out of those offered the program, expressed as a percentage. Adherence refers to the proportion of the 24 prescribed trainings attended. Patients attending more than 75% of the total training sessions are considered completers.
Time frame: Day 0, Week 9
Plan to share: Yes — All IPD that underlie results in a publication
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 2 months and ending 2 years after the publication of results
Access criteria: Individual participant data (IPD) underlying published results will be shared with qualified researchers whose analyses aim to advance cardiac rehabilitation science. Requests must include a research proposal detailing objectives, planned analyses, and statistical methods, which may require independent review. Approved applicants must sign a data-sharing agreement. Requests should be submitted to the principal investigator via email. Proposals will be reviewed by a data access committee based on scientific merit, ethical compliance, and consistency with participant consent.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 12 months is below that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.